로딩 중…
지수 로딩 중…
Tarsus Pharmaceuticals, Inc.
TARS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$61.32+3.86%
2026-08-03
Financials
Valuation Metrics
Tarsus Pharmaceuticals, Inc.'s Market Cap is $2.64B. At end of 2025 it was $3.50B. Ranked #1874 of 3,112 in US market (top 60%), #689 of 1,445 on NASDAQ (top 48%), #110 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.64B | US#1,874/3,112 Sec#110/269 |
| Revenue | $535M | US#2,318/3,112 Sec#79/269 |
| Net Income | $-48M | US—/3,112 Sec—/269 |
| Total Assets | $581M | US#2,689/3,112 Sec#138/269 |
| Net Assets | $349M | US#2,472/3,112 Sec#148/269 |
| Value | ||
| P/B | 7.56x | US#2,459/3,112 Sec#181/269 |
| P/S | 4.93x | US#2,257/3,112 Sec#77/269 |
| FCF Yield | -1.20% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -13.83% | US#2,461/3,112 Sec#92/269 |
| ROA | -8.31% | US#2,616/3,112 Sec#98/269 |
| Op. Margin | -9.50% | US#2,627/3,112 Sec#97/269 |
| Revenue Growth | 106.87% | US#129/3,112 Sec#28/269 |
| Financial Health | ||
| Debt Ratio | 66.54% | US#736/3,112 Sec#152/269 |
| Total Debt | $89M | US#2,415/3,112 Sec#122/269 |
| FCF | $-32M | US#2,416/3,112 Sec#103/269 |
| Cash | $102M | US#2,202/3,112 Sec#176/269 |
| Current Ratio | 3.74x | US#617/3,112 Sec#173/269 |
| Performance | ||
| 1Y Return | 50.26% | US#818/3,112 Sec#126/269 |
| 1M Return | -6.30% | US#2,355/3,112 Sec#135/269 |
| From 52W High | -28.07% | US#2,086/3,112 Sec#154/269 |
| 1Y MDD | -32.00% | US#1,513/3,112 Sec#96/269 |
| Trading | ||
| Volume | 797,143 shares | US#1,689/3,112 Sec#159/269 |
| Trading Value | $49M | US#1,377/3,112 Sec#88/269 |
| Per Share | ||
| EPS | $-1.55 | US—/3,112 Sec—/269 |
| BPS | $8.03 | US#1,939/3,112 Sec#84/269 |